Results per Page:
A tale of two T-cells: comparing liso-cel and axi-cel for treatment of refractory large B-cell lymphoma
From the Gauthier group, Clinical Research Division
From data to decisions: Enhancing CAR T-cell therapy with predictive modeling
From the Gauthier Group, Clinical Research Division
Automated, fast and accurate method to grade ICAHT, a CAR T-cell therapy side effect
From Dr. Emily Liang, Dr. Jordan Gauthier and colleagues, Clinical Research Division
Fred Hutch and UW hematology-oncology fellows win ASCO Young Investigator Awards
Winners represent broad range of research
Effective immunotherapy for relapsed or treatment-resistant leukemia
From Dr. Jordan Gauthier and colleagues, Clinical Research Division
Potential strategies for mitigating CD19 CAR T-cell associated toxicities
From the Gauthier Group, Clinical Research Division
Fred Hutch at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots — and more
The 62nd American Society of Hematology Annual Meeting and Exposition to be held virtually Dec. 5-8, 2020
If at first you don’t succeed: Testing outcomes of second CAR T-cell infusions
From the Turtle group and collaborators, Clinical Research Division
Science on the horizon
Fred Hutch experts make predictions for science trends, advances in 2020
Try, try again: Can a 2nd dose of CAR T cells succeed when the first fails?
First-of-its-kind study offers early indication of factors linked to increased odds of success for patients out of options